National Research (NASDAQ:NRCIA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a note issued to investors on Thursday.

According to Zacks, “National Research Corporation offers analytics and insights that facilitate revenue growth, patient, employee, customer retention and patient engagement for healthcare providers, payers and other healthcare organizations. Its services include capture, interpretation, transmittal and benchmarking of critical data elements from various healthcare consumers. National Research Corporation is headquartered in Lincoln, Nebraska. “

How to Become a New Pot Stock Millionaire

Separately, BidaskClub raised National Research from a “hold” rating to a “buy” rating in a report on Friday, January 26th.

Shares of National Research stock opened at $31.20 on Thursday. National Research has a twelve month low of $18.81 and a twelve month high of $41.99. The stock has a market capitalization of $773.28, a PE ratio of 60.00 and a beta of 1.75.

In other National Research news, CEO Michael D. Hays sold 1,602,399 shares of the business’s stock in a transaction that occurred on Thursday, January 25th. The stock was sold at an average price of $39.03, for a total transaction of $62,541,632.97. Following the sale, the chief executive officer now directly owns 5,261,410 shares of the company’s stock, valued at $205,352,832.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John N. Nunnelly sold 2,383 shares of the business’s stock in a transaction that occurred on Friday, March 16th. The stock was sold at an average price of $31.74, for a total value of $75,636.42. Following the sale, the director now directly owns 31,842 shares in the company, valued at $1,010,665.08. The disclosure for this sale can be found here. Insiders have sold 6,866,192 shares of company stock worth $164,215,096 over the last three months. 5.70% of the stock is currently owned by insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of NRCIA. Citadel Advisors LLC purchased a new position in shares of National Research during the third quarter valued at approximately $500,000. Schwab Charles Investment Management Inc. boosted its position in shares of National Research by 22.2% during the third quarter. Schwab Charles Investment Management Inc. now owns 37,212 shares of the business services provider’s stock valued at $1,403,000 after buying an additional 6,759 shares during the period. Hillsdale Investment Management Inc. boosted its position in shares of National Research by 22.1% during the third quarter. Hillsdale Investment Management Inc. now owns 33,100 shares of the business services provider’s stock valued at $1,248,000 after buying an additional 6,000 shares during the period. Wasatch Advisors Inc. boosted its position in shares of National Research by 16.2% during the third quarter. Wasatch Advisors Inc. now owns 73,216 shares of the business services provider’s stock valued at $2,760,000 after buying an additional 10,216 shares during the period. Finally, Wells Fargo & Company MN boosted its position in shares of National Research by 75.2% during the third quarter. Wells Fargo & Company MN now owns 9,450 shares of the business services provider’s stock valued at $356,000 after buying an additional 4,056 shares during the period. 33.66% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: This piece of content was first posted by Watch List News and is the property of of Watch List News. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of international copyright laws. The original version of this piece of content can be accessed at https://www.watchlistnews.com/zacks-investment-research-lowers-national-research-nrcia-to-hold/1955015.html.

About National Research

National Research Corporation, doing business as NRC Health, is a provider of analytics and insights for healthcare providers, payers and other healthcare organizations. The Company operates through six segments: Experience, The Governance Institute, Market Insights, Transparency, National Research Corporation Canada and Connect.

Get a free copy of the Zacks research report on National Research (NRCIA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for National Research Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for National Research and related companies with MarketBeat.com's FREE daily email newsletter.